|
1
|
Vardiman JW, Harris NL and Brunning RD:
The World Health Organization (WHO) classification of the myeloid
neoplasms. Blood. 100:2292–2302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Geyer JT and Orazi A: Myeloproliferative
neoplasms (BCR-ABL1 negative) and
myelodysplastic/myeloproliferative neoplasms: Current diagnostic
principles and upcoming updates. Int J Lab Hematol. 38(Suppl 1):
S12–S19. 2016. View Article : Google Scholar
|
|
3
|
Orazi A and Germing U: The
myelodysplastic/myeloproliferative neoplasms: Myeloproliferative
diseases with dysplastic features. Leukemia. 22:1308–1319. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mughal TI, Cross NC, Padron E, Tiu RV,
Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ,
Garcia-Manero G, et al: An International MDS/MPN Working Group's
perspective and recommendations on molecular pathogenesis,
diagnosis and clinical characterization of
myelodysplastic/myeloproliferative neoplasms. Haematologica.
100:1117–1130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shibata A, Bennett JM, Castoldi GL,
Catovsky D, Flandrin G, Jaffe ES, Katayama I, Nanba K, Schmalzl F,
Yam LT, et al: Recommended methods for cytological procedures in
haematology. International Committee for Standardization in
Haematology (ICSH). Clin Lab Haematol. 7:55–74. 1985.
|
|
6
|
Wu H, Bian S, Chu J, Zhong X, Sun H, Zhang
B and Lu Z: Characteristics of the four subtypes of
myelodysplastic/myeloproliferative neoplasms. Exp Ther Med.
5:1332–1338. 2013.PubMed/NCBI
|
|
7
|
Beran M, Wen S, Shen Y, Onida F, Jelinek
J, Cortes J, Giles F and Kantarjian H: Prognostic factors and risk
assessment in chronic myelomonocytic leukemia: Validation study of
the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma.
48:1150–1160. 2007. View Article : Google Scholar
|
|
8
|
Germing U, Strupp C, Knipp S, Kuendgen A,
Giagounidis A, Hildebrandt B, Aul C, Haas R, Gattermann N and
Bennett JM: Chronic myelomonocytic leukemia in the light of the WHO
proposals. Haematologica. 92:974–977. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parikh SA and Tefferi A: Chronic
myelomonocytic leukemia: 2013 update on diagnosis, risk
stratification, and management. Am J Hematol. 87:610–619. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Benton CB, Nazha A, Pemmaraju N and
Garcia-Manero G: Chronic myelomonocytic leukemia: Forefront of the
field in 2015. Crit Rev Oncol Hematol. 95:222–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koldehoff M, Steckel NK, Hegerfeldt Y,
Ditschkowski M, Beelen DW and Elmaagacli AH: Clinical course and
molecular features in 21 patients with atypical chronic myeloid
leukemia. Int J Lab Hematol. 34:e3–e5. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vardiman JW, Thiele J, Arber DA, Brunning
RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM,
Hellstrom-Lindberg E, Tefferi A and Bloomfield CD: The 2008
revision of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: rationale and important
changes. Blood. 114:937–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Breccia M, Biondo F, Latagliata R,
Carmosino I, Mandelli F and Alimena G: Identification of risk
factors in atypical chronic myeloid leukemia. Haematologica.
91:1566–1568. 2006.PubMed/NCBI
|
|
14
|
Xubo G, Xingguo L, Xianguo W, Rongzhen X,
Xibin X, Lin W, Lei Z, Xiaohong Z, Genbo X and Xiaoying Z: The role
of peripheral blood, bone marrow aspirate and especially bone
marrow trephine biopsy in distinguishing atypical chronic myeloid
leukemia from chronic granulocytic leukemia and chronic
myelomonocytic leukemia. Eur J Haematol. 83:292–301. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang SA, Hasserjian RP, Fox PS, Rogers HJ,
Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J,
Kanagal-Shamanna R, et al: Atypical chronic myeloid leukemia is
clinically distinct from unclassifiable
myelodysplastic/myeloproliferative neoplasms. Blood. 123:2645–2651.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Onida F, Ball G, Kantarjian HM, Smith TL,
Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ and Beran M:
Characteristics and outcome of patients with Philadelphia
chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Cancer. 95:1673–1684. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Triantafyllidis I, Ciobanu A, Stanca O,
Draghici C, Angelescu S and Tapelea E: Peculiarities in the
Diagnosis Approach of MDS/MPN-U Patients. Maedica (Buchar).
7:173–176. 2012.PubMed/NCBI
|
|
18
|
Seo JY, Lee KO, Kim SH, Kim K, Jung CW,
Jang JH and Kim HJ: Clinical significance of SF3B1 mutations in
Korean patients with myelodysplastic syndromes and
myelodysplasia/myeloproliferative neoplasms with ring sideroblasts.
Ann Hematol. 93:603–608. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
DiNardo CD, Daver N, Jain N, Pemmaraju N,
Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian
HM, et al: Myelodysplastic/myeloproliferative neoplasms,
unclassifiable (MDS/MPN, U): Natural history and clinical outcome
by treatment strategy. Leukemia. 28:958–961. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hyjek E and Vardiman JW:
Myelodysplastic/myeloproliferative neoplasms. Semin Diagn Pathol.
28:283–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goasguen JE, Bennett JM, Bain BJ, Vallespi
T, Brunning R and Mufti GJ: International Working Group on
Morphology of Myelodysplastic Syndrome: Morphological evaluation of
monocytes and their precursors. Haematologica. 94:994–997. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hall J and Foucar K: Diagnosing
myelodysplastic/myeloproliferative neoplasms: Laboratory testing
strategies to exclude other disorders. Int J Lab Hematol.
32:559–571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vermi W, Facchetti F, Rosati S, Vergoni F,
Rossi E, Festa S, Remotti D, Grigolato P, Massarelli G and Frizzera
G: Nodal and extranodal tumor-forming accumulation of plasmacytoid
monocytes/interferon-producing cells associated with myeloid
disorders. Am J Surg Pathol. 28:585–595. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tiu RV and Sekeres MA: Making sense of the
myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Curr Opin Hematol. 21:131–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cazzola M, Malcovati L and Invernizzi R:
Myelodysplastic/myeloproliferative neoplasms. Hematology Am Soc
Hematol Educ Program. 2011:264–272. 2011.PubMed/NCBI
|
|
26
|
Kern W, Bacher U, Schnittger S, Alpermann
T, Haferlach C and Haferlach T: Multiparameter flow cytometry
reveals myelodysplasia-related aberrant antigen expression in
myelodysplastic/myeloproliferative neoplasms. Cytometry B Clin
Cytom. 84:194–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
